Clinicopathological Features and Outcomes of Gastrointestinal Stromal Tumours in Oman: A Multi-centre Study

Overview

Journal Sultan Qaboos Univ Med J

Specialty General Medicine

Date 2021 Jul 5

PMID 34221471

Authors

Zainab Al-Maqrashi

Ikram A Burney

Kadhim M Taqi

Yaqoob Al-Sawafi

Asim Qureshi

Ritu Lakhtakia

Itrat Mehdi

Bassim Al-Bahrani

Shiyam Kumar

Mansour Al-MoundhrI

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aimed to report the clinicopathological features, management and long-term outcomes of patients with gastrointestinal stromal tumours (GISTs) in Oman.

Methods: This retrospective study was conducted on patients treated for GIST between January 2003 and December 2017 at three tertiary referral centres in Muscat, Oman. All patients with confirmed histopathological diagnoses of GIST and followed-up at the centres during this period were included. Relevant information was retrieved from hospital records until April 2019.

Results: A total of 44 patients were included in the study. The median age was 55.5 years and 56.8% were female. The most common primary site of disease was the stomach (63.6%) followed by the jejunum/ileum (18.2%). Two patients (4.5%) had -negative, -positive disease. A total of 24 patients (54.5%) presented with localised disease and eight (33.3%) were classified as being at high risk of relapse. Patients with metastatic disease received imatinib in a palliative setting, whereas those with completely resected disease in the intermediate and high-risk groups were treated with adjuvant imatinib. Of the six patients (13.6%) with progressive metastatic disease, of which four had mutations on exon 11 and one on exon 9, while one had wild-type disease. Overall, rates of progression-free survival and overall survival (OS) at 100 months were 77.4% and 80.4%, respectively. Rates of OS for patients with localised and metastatic disease were 89.9% and 80.2%, respectively.

Conclusion: The presenting features and outcomes of patients with GISTs in Oman were comparable to those reported in the regional and international literature.

References

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

Cavaliere D, Griseri G, Venturino E, Schirru A, Cosce U, Caristo I . Management of patients with gastrointestinal stromal tumors: experience from an Italian hospital. Tumori. 2006; 91(6):467-71. DOI: 10.1177/030089160509100604. View

. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010; 28(7):1247-53. PMC: 2834472. DOI: 10.1200/JCO.2009.24.2099. View

Joensuu H, Eriksson M, Hall K, Hartmann J, Pink D, Schutte J . One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307(12):1265-72. DOI: 10.1001/jama.2012.347. View

Miettinen M, Lasota J . Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23(2):70-83. DOI: 10.1053/j.semdp.2006.09.001. View

Joensuu H . Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39(10):1411-9. DOI: 10.1016/j.humpath.2008.06.025. View

Takahashi T, Nakajima K, Nishitani A, Souma Y, Hirota S, Sawa Y . An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol. 2007; 12(5):369-74. DOI: 10.1007/s10147-007-0705-7. View

Yacob M, Inian S, Sudhakar C . Gastrointestinal Stromal Tumours: Review of 150 Cases from a Single Centre. Indian J Surg. 2016; 77(Suppl 2):505-10. PMC: 4692851. DOI: 10.1007/s12262-013-0899-z. View

Fletcher C, Berman J, Corless C, Gorstein F, Lasota J, Longley B . Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002; 33(5):459-65. DOI: 10.1053/hupa.2002.123545. View

10.

Miettinen M, Lasota J . Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006; 130(10):1466-78. DOI: 10.5858/2006-130-1466-GSTROM. View

11.

Ud Din N, Ahmad Z, Arshad H, Idrees R, Kayani N . Gastrointestinal Stromal Tumors: A Clinicopathologic and Risk Stratification Study of 255 Cases from Pakistan and Review of Literature. Asian Pac J Cancer Prev. 2015; 16(12):4873-80. DOI: 10.7314/apjcp.2015.16.12.4873. View

12.

DeMatteo R, Gold J, Saran L, Gonen M, Liau K, Maki R . Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2007; 112(3):608-15. DOI: 10.1002/cncr.23199. View

13.

Miettinen M, Sarlomo-Rikala M, Lasota J . Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999; 30(10):1213-20. DOI: 10.1016/s0046-8177(99)90040-0. View

14.

Al Hussaini H . GIST in Saudi Arabia: multicentric histopathological genetic study of 75 surgically excised cases. Gulf J Oncolog. 2012; (11):31-7. View

15.

Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G . Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002; 3(11):655-64. DOI: 10.1016/s1470-2045(02)00899-9. View

16.

Barakat F, Haddad H, Matalka I, Al-Orjani M, Al-Masri M, Sughayer M . Characteristics of gastrointestinal stromal tumors in a Middle Eastern population. Saudi Med J. 2010; 31(7):797-802. View

17.

McDonnell M, Punnoose S, Viswanath Y, Wadd N, Dhar A . Gastrointestinal stromal tumours (GISTs): an insight into clinical practice with review of literature. Frontline Gastroenterol. 2017; 8(1):19-25. PMC: 5369437. DOI: 10.1136/flgastro-2015-100670. View

18.

Mucciarini C, Rossi G, Bertolini F, Valli R, Cirilli C, Rashid I . Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer. 2007; 7:230. PMC: 2241631. DOI: 10.1186/1471-2407-7-230. View

19.

Corless C, Ballman K, Antonescu C, Kolesnikova V, Maki R, Pisters P . Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014; 32(15):1563-70. PMC: 4026579. DOI: 10.1200/JCO.2013.51.2046. View

20.

West R, Corless C, Chen X, Rubin B, Subramanian S, Montgomery K . The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004; 165(1):107-13. PMC: 1618538. DOI: 10.1016/S0002-9440(10)63279-8. View